After obtaining PMDA/NMPA formal endorsement of a proposed development strategy, Ascent provides comprehensive regulatory and Phase 1-4 clinical trial management support throughout the Asia-Pacific region. The Ascent team, in collaboration with partners, can implement trials in Japan, China, Korea, Australia, and Southeast Asia, and selects sites from a range of countries in line with the particular needs of each program. Ascent understands that many emerging pharma companies approach Asia with no thought of directly implementing trials in the region. However, throughout the process of development planning, companies often come to understand that the incremental increases in costs and complexity required to include Asian sites in global clinical trials allows companies to realize exponential growth in Asian product value. For companies that decide to independently include Asia in multinational clinical trials, Ascent can provide comprehensive support of clinical trial implementation throughout the region.